The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Prelude Therapeutics Inc (NASDAQ: PRLD) closed the day trading at $1.14 down -5.79% from the previous closing price of $1.21. In other words, the price has decreased by -$5.79 from its previous closing price. On the day, 0.24 million shares were traded. PRLD stock price reached its highest trading level at $1.2581 during the session, while it also had its lowest trading level at $1.13.
Ratios:
For a better understanding of PRLD, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.04 and its Current Ratio is at 7.04. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
On June 20, 2024, Barclays Downgraded its rating to Underweight which previously was Equal Weight but kept the price unchanged to $3.
On March 13, 2024, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $7.JMP Securities initiated its Mkt Outperform rating on March 13, 2024, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 31 ’24 when Vaddi Krishna bought 5,000 shares for $1.21 per share. The transaction valued at 6,044 led to the insider holds 142,553 shares of the business.
Vaddi Krishna bought 10,000 shares of PRLD for $12,000 on Dec 30 ’24. The CEO now owns 137,553 shares after completing the transaction at $1.20 per share. On Dec 23 ’24, another insider, Combs Andrew, who serves as the Chief Chemistry Officer of the company, bought 60,000 shares for $1.37 each. As a result, the insider paid 82,002 and bolstered with 377,623 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRLD now has a Market Capitalization of 62740128 and an Enterprise Value of -72749904. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.91 while its Price-to-Book (P/B) ratio in mrq is 0.40. Its current Enterprise Value per Revenue stands at -24.25 whereas that against EBITDA is 0.514.
Stock Price History:
The Beta on a monthly basis for PRLD is 1.38, which has changed by -0.70542634 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, PRLD has reached a high of $6.80, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 2.51%, while the 200-Day Moving Average is calculated to be -65.60%.
Shares Statistics:
Over the past 3-months, PRLD traded about 480.88K shares per day on average, while over the past 10 days, PRLD traded about 418570 shares per day. A total of 42.18M shares are outstanding, with a floating share count of 21.67M. Insiders hold about 60.63% of the company’s shares, while institutions hold 35.27% stake in the company. Shares short for PRLD as of 1734048000 were 3260206 with a Short Ratio of 6.78, compared to 1731628800 on 2896842. Therefore, it implies a Short% of Shares Outstanding of 3260206 and a Short% of Float of 18.8.
Earnings Estimates
A detailed examination of Prelude Therapeutics Inc (PRLD) is currently in progress, with 4.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.38 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.77 and -$1.78 for the fiscal current year, implying an average EPS of -$1.77. EPS for the following year is -$1.5, with 4.0 analysts recommending between -$0.68 and -$2.03.
